Global Anterior Uveitis Share 2025, Forecast To 2034
26 Mar, 2025
What Has Been the Progress and Growth of the Anterior Uveitis Market in Recent Years?
The anterior uveitis market has seen considerable growth due to a variety of factors.
• In recent years, the market size of anterior uveitis has significantly expanded. It is projected to increase from $0.51 billion in 2024 to $0.58 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%.
Such growth during the historic period can be traced back to factors such as the increasing occurrence of autoimmune disorders, enhanced awareness about eye health, better accessibility to healthcare services, the increasing usage of corticosteroids and biologics, extending research into immunological pathways, and the rising number of elderly people.
What Can Be Expected from the Anterior Uveitis Market By 2029?
The anterior uveitis market is expected to maintain its strong growth trajectory in upcoming years.
• The market for anterior uveitis is anticipated to significantly expand in the upcoming years. The market is predicted to escalate to a value of $0.89 billion in 2029, with a compound annual growth rate (CAGR) of 11.6%.
The predicted market expansion within the estimated period can be credited to the increased awareness of autoimmune diseases, the extensive use of biologic therapy, the escalating occurrence of inflammatory conditions, enhanced healthcare spending, and consistent exploration into personalized medicine. The leading trends for the forecasted period include progression in novel biologics, implementation of corticosteroid delivery mechanisms, sophisticated diagnostic imaging, individualized medicine methods, focused immunomodulators, application of minimally invasive surgical procedures, and advancements in digital health technology.
Which Key Drivers Are Propelling The Anterior Uveitis Market's Growth?
The growth of the anterior uveitis market is anticipated to be driven by the increasing occurrences of autoimmune diseases. When the immune system mistakenly starts attacking the body's own cells and tissues as if they were foreign invaders, it results in autoimmune diseases. This mistaken attack leads to inflammation and damage to various bodily systems and organs. Genetic predispositions, changes in lifestyle, environmental factors, and improved diagnosis due to heightened awareness, all contribute to the rise of autoimmune diseases. Anterior uveitis, which induces inflammation in the anterior segment of the eye, commonly appears in autoimmune diseases. It is often connected with conditions such as rheumatoid arthritis and ankylosing spondylitis. For example, Versorgungsatlas.de, a Germany-based organisation, reported in November 2024 that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease. This equates to a raw prevalence rate of 8.61%. As a result, the growing occurrence of autoimmune diseases is propelling the growth of the anterior uveitis market.
How Is The Anterior Uveitis Market segmented?
The anterior uveitis market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatments, Surgical Treatments, Biologic Therapy
2) By Diagnosis Method: Clinical Diagnosis, Diagnostic Imaging, Biomarkers
3) By Cause: Infectious, Non-Infectious
4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Pharmacological Treatments: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Immunosuppressive Drugs
2) By Surgical Treatments: Cataract Surgery, Glaucoma Surgery, Vitrectomy
3) By Biologic Therapy: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Monoclonal Antibodies
What New Trends Are Influencing The Anterior Uveitis Market?
Leading businesses in the anterior uveitis market are concentrating their efforts on introducing advanced drug formulas, such as eye drops, aimed at enhancing patient satisfaction, boosting drug delivery, and minimizing inflammation with less side effects. Eye drops are commonly used in managing inflammation, relieving pain, and averting possible complications in anterior uveitis treatment. For example, Tarsier Pharma Ltd., a pharmaceutical company based in Israel, obtained approval from the U.S. Food and Drug Administration (FDA) for the Tarsier-04 Phase 3 trial's clinical protocol and statistical evaluation under a Special Protocol Assessment (SPA) in January 2024. This trial seeks to determine the efficacy of TRS01 eye drops in the treatment of non-infectious uveitis, including uveitic glaucoma. The Tarsier-04 trial is a broad-scale, randomized, double-masked, active-controlled investigation, which aims to enroll up to 300 patients from the U.S., aiming to confirm the safety and efficacy of TRS01, especially in controlling inflammation without raising glaucoma risk.
Who Are the Key Players In The Anterior Uveitis Market?
Major companies operating in the anterior uveitis market are:
• AbbVie Inc.
• Novartis AG
• Amgen Inc.
• Aerie Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• UCB S.A.
• Bausch & Lomb Incorporated
• Cipla Ltd.
• Hikma Pharmaceuticals PLC
• Cadila Pharmaceuticals Ltd.
• Santen Pharmaceutical Co. Ltd.
• HanAll Biopharma Co. Ltd.
• EyePoint Pharmaceuticals Inc.
• Kiora Pharmaceuticals Inc.
• Clearside Biomedical Inc.
• Oculis SA
• Aldeyra Therapeutics Inc.
• Lux Biosciences Inc.
• Tarsier Pharma Ltd.
• Xoma Corporation.
What Is The Most Dominant Region In The Anterior Uveitis Market?
North America was the largest region in the anterior uveitis market in 2024. The regions covered in the anterior uveitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.